STANDARD BIOTOOLS INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
ARCHIMED Life Science Tools Services completed its acquisition of Standard BioTools' Microfluidics Business on November 3, 2026. The business now operates independently as Biomark Scientific under ARCHIMED ownership. The filing does not disclose the acquisition price, transaction terms, or financial impact to Standard BioTools.
Why this rating
Material divestiture of a business unit, but no price disclosed. Unclear what fraction of Standard BioTools' revenue/EBITDA this represents relative to $291M market cap. Appears part of restructuring alongside Treeline merger and Element sale.
Price action (we called it neutral)
at our read · unknown $0.60 | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.